Research Square
Semaglutide reduces proteomic organ-specific biological age across randomized clinical trials
Preprint: randomised trial in 10,052 peopleSemaglutide
Papers by Filip K. Knop
6 results
- AHA Scientific Sessions 2025 Abstract
Lower Risk of Cardiovascular Events in Patients with Heart Failure Initiated on Semaglutide 2.4 mg in the Real-world: Results from the SCORE-HF Study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World – Heart Failure Population)
Study in peopleInterventions - AHA Scientific Sessions 2025 Abstract
Lower Risk of Cardiovascular Events in Patients with Clinical Atherosclerotic Cardiovascular Disease Initiated on Semaglutide 2.4 mg in the Real-world: Results from the SCORE-Clinical ASCVD Study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World – Clinical Atherosclerotic Cardiovascular Disease Population)
Study in peopleInterventions
- ADA Scientific Sessions 2025 Abstract
The Glucagonotropic Effect of Glucose-Dependent Insulinotropic Polypeptide Is Negated during Insulin-Induced Hypoglycemia in Persons with Type 1 Diabetes
Trial in peopleInterventions - ADA Scientific Sessions 2025 Abstract
GIP Alone or with GLP-1RA Had No Detectable Effect on Glucose Levels in Individuals with Type 2 Diabetes
Trial in peopleInterventions